Skip to main content
. Author manuscript; available in PMC: 2018 Jan 1.
Published in final edited form as: Clin Cancer Res. 2016 Jun 27;23(1):193–203. doi: 10.1158/1078-0432.CCR-16-0040

Figure 5. Adaptive immune response-related resistance accounts for antibody therapy resistance.

Figure 5

(A-B) A20-bearing WT BALB/c mice (n = 5/group) were administered 100 μg of anti-mCD20 or hIgG on day 11 (A) or day 25 (B). (C) The LN, spleen and tumor from naïve (WT) or tumor-bearing (small and large established) WT BALB/c mice were collected and stained for Treg cells. (D) Macrophages (CD11b+ F4/80+), MDSCs (CD11b+ Gr-1Hi) and Treg cells (CD4+ Foxp3+) in large advanced B-cell lymphoma were detected by FACS staining. (E) CTLA-4 expression of Tregs in the LN, spleen, and tumor of naïve and large established tumor-bearing WT BALB/c mice was detected by FACS staining. The mean ± SEM values are shown.